-
Innovation Ranking
NewInnovation Ranking – The Progressive Corp
The Progressive Corp (Progressive) is an insurance holding company. It offers a range of personal and commercial automobile insurance, and specialty property-casualty insurance and other related services. It offers insurance products for motorcycles, all-terrain vehicles, recreational vehicles, manufactured homes, boat, floods, renters, general liability, professional liability, workers compensation, umbrella, watercraft, and snowmobiles. It also operates a property business and provides residential property insurance for homeowners, other property owners and renters. It markets and distributes insurance products through independent insurance agents...
-
Innovation Ranking
NewInnovation Ranking – Progress Software Corp
Progress Software Corp (Progress) providers application development, data integration and data analysis solutions. The company’s solutions and platforms comprises of development and management of business applications. It also offers application modernization, infrastructure automation, development operations, data management, managed database services, performance enhancements and tuning, and analytics/business intelligence services. Progress markets its products through direct sales force and indirect channel partners; and distributes offerings through resellers, systems integrators, distributors, and OEM partners. It serves business enterprises, application developers, and app users....
-
Product Insights
NewLikelihood of Approval Analysis for Primary Progressive Multiple Sclerosis (PPMS)
Overview How likely is it that the drugs in Primary Progressive Multiple Sclerosis (PPMS) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Primary Progressive Multiple Sclerosis (PPMS) Overview Primary progressive multiple...
-
Product Insights
NewLikelihood of Approval Analysis for Secondary Progressive Multiple Sclerosis (SPMS)
Overview How likely is it that the drugs in Secondary Progressive Multiple Sclerosis (SPMS) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Secondary Progressive Multiple Sclerosis (SPMS) Overview Secondary progressive multiple...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Progressive Multifocal Leukoencephalopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Progressive Multifocal Leukoencephalopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Progressive Multifocal Leukoencephalopathy Drug Details: Pembrolizumab (Keytruda) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Censavudine in Progressive Supranuclear Palsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Censavudine in Progressive Supranuclear Palsy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Censavudine in Progressive Supranuclear Palsy Drug Details: Censavudine (Festinavir, BMS-986001,OBP-601)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OLX-07010 in Progressive Supranuclear Palsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OLX-07010 in Progressive Supranuclear Palsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OLX-07010 in Progressive Supranuclear Palsy Drug Details: OLX-07010 inhibitor is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Remibrutinib in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Remibrutinib in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Remibrutinib in Secondary Progressive Multiple Sclerosis (SPMS) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Foralumab in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Foralumab in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Foralumab in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Frexalimab in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Frexalimab in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Frexalimab in Secondary Progressive Multiple Sclerosis (SPMS) Drug...